Treatment of HER-2-positive breast cancers includes the use of monoclonal antibodies such as trastuzumab or pertuzumab, kinase inhibitors, or different antibody-drug conjugates such as trastuzumab-deruxtecan or trastuzumab-emtansine [10,11]. The gene discussed is ERBB2; the disease is breast carcinoma.